Sanctuary Advisors LLC Acquires 49,064 Shares of Haleon plc (NYSE:HLN)

Sanctuary Advisors LLC lifted its holdings in Haleon plc (NYSE:HLN) by 25.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 245,310 shares of the company’s stock after buying an additional 49,064 shares during the quarter. Sanctuary Advisors LLC’s holdings in Haleon were worth $2,367,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Fortitude Family Office LLC bought a new position in shares of Haleon in the third quarter valued at about $28,000. Toronto Dominion Bank raised its holdings in shares of Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company’s stock valued at $38,000 after buying an additional 3,470 shares during the last quarter. Cultivar Capital Inc. bought a new stake in Haleon during the 2nd quarter worth about $40,000. Prospera Private Wealth LLC bought a new stake in Haleon during the 3rd quarter worth about $57,000. Finally, BOKF NA raised its holdings in Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after purchasing an additional 2,842 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Stock Performance

Shares of NYSE:HLN opened at $9.93 on Wednesday. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $44.93 billion, a P/E ratio of 29.19, a P/E/G ratio of 2.95 and a beta of 0.28. The business has a 50-day moving average price of $9.74 and a two-hundred day moving average price of $9.54. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Morgan Stanley boosted their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. UBS Group raised Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Haleon presently has an average rating of “Buy” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.